Dinaciclib
As of the edition of 20 October 2026, Dinaciclib is a small molecule: stopped in 2022; acts on CDK1, CDK2 and CDK5 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Small molecule
- Registered trials
- 18, 5 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Heart and blood vessels; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
8 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product8 company-target rows are on route A because of Dinaciclib.
See the 8 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 10 | 7 | 1 | 2 |
| Phase 2 | 7 | 3 | 1 | 3 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 18 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Lead sponsor of trials | 2006 to now |
| AbbVie | Lead sponsor of trials | 2018 to now |